Quarterly ResultMay 7, 2026, 04:38 PM
Jade Biosciences Q1 Net Loss $(40.4)M; Cash & Investments $311.3M
AI Summary
Jade Biosciences reported a net loss of $(40.4) million for the three months ended March 31, 2026, an increase from $(38.2) million in the prior year period. Operating expenses significantly increased, driven by higher research and development and general and administrative costs. Despite increased cash burn from operations, the company maintains a strong liquidity position with $311.3 million in cash and investments, which is expected to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $(40.4) million, up from $(38.2) million in Q1 2025.
- Cash and cash equivalents decreased to $55.1 million from $88.4 million at Dec 31, 2025.
- Investments increased to $256.2 million from $247.7 million at Dec 31, 2025.
- Total cash and investments stood at $311.3 million as of March 31, 2026.
- Research and development expenses rose to $36.1 million from $20.0 million year-over-year.
- General and administrative expenses increased to $7.4 million from $3.4 million year-over-year.
- Net cash used in operating activities was $(24.1) million, up from $(18.8) million year-over-year.
- Weighted-average common shares increased to 57.8 million from 3.2 million year-over-year.
Price Impact
More from JBIO